Patch-in-a-Can technology to delivery pain management product
MedPharm licenses its MedSpray ‘Patch-in-a-Can’ technology to Virpax Pharmaceuticals.
MedPharm has licensed its unique MedSpray technology to Virpax Pharmaceuticals, a company that specialises in developing pharmaceutical products for pain management by using new drug delivery systems. MedSpray is covered by worldwide patents and delivers transdermal patch technology in a metered-dose aerosol spray. The thin film patch created on the skin or mucosal membrane has been demonstrated in clinical trials to provide long-lasting efficacy for patients.
MedPharm is working closely with Virpax to develop DSF100 (NSAID spray film 1.3%), an investigational spray film designed to deliver an NSAID transdermally via a metered-dose spray. The delivery system features a high level of adhesiveness, accessibility and skin drying. Virpax filed a pre-IND meeting request with the FDA and it was granted on 18 May 2018.
“MedSpray’s unique dosing offers clients the opportunity to differentiate their product and potentially achieve premium pricing for extended effects,” said Dr Jeremy Drummond, MedPharm’s SVP of Business Development. “We are looking forward to partnering with Virpax to bring products with our MedSpray technology to market.”
“We believe there is an opportunity to explore the development of non-opioid transdermal pain treatments that improve on existing gel and patch products, for which adhesion and accessibility can be a challenge,” said Anthony Mack, CEO of Virpax. “We believe that the ‘Patch-in-a-Can’ technology offers a promising delivery system and we are excited to be collaborating with a world leader like MedPharm.”
During the last 20 years, MedPharm has built a worldwide reputation for helping clients navigate the complex route to successful development of its pharmaceutical products. In parallel with fees for service work, MedPharm is constantly looking for opportunities to develop new formulation and drug delivery technologies such as MedSpray, which enhances clients’ products, provides clinical benefits for patients and meets the increasingly stringent requirements of regulatory authorities.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance